Findings

What do systematic reviews say?

100 questions · 100 findings · 41 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 31 · 31%GRADE not reported 4 · 4%Very low 34 · 34%Low 19 · 19%Moderate 10 · 10%High 2 · 2%

Intervention not reported

Serious adverse events (number) · people with acute pancreatitis

1 finding from 1 review

Pharmacological interventions for acute pancreatitis 2017 · Cochrane Headline outcomes only
0.86 [0.68, 1.07]
12 studies · 716 participants
Very low

Colchicine vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Insulin plus glucagon vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propylthiouracil vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glucocorticosteroids vs no intervention

Serious adverse events (number) · participants with severe alcoholic hepatitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pentoxifylline vs no intervention

Serious adverse events (number) · participants with severe alcoholic hepatitis

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Anabolic steroids vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Glucocorticosteroids vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Antioxidants vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Colchicine vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Propylthiouracil vs no intervention

Serious adverse events (number) · alcohol‐related disorders (others)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pentoxifylline vs no intervention

Serious adverse events (number) · participants with alcoholic hepatitis (all severity)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological interventions for alcoholic liver disease (alcohol‐related liver disease) 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Enhanced recovery protocol vs usual care

Serious adverse events (number) · people with major upper gastrointestinal, liver and pancreatic surgery

It is very uncertain whether enhanced recovery protocol changes serious adverse events (number) compared with standard care (very low certainty).

1 finding from 1 review

Enhanced recovery protocols for major upper gastrointestinal, liver and pancreatic surgery 2016 · Cochrane Headline outcomes only
Rate ratio 0.72 [0.45, 1.13]
7 studies · 859 participants
Very low

Anti‐TNF discontinuation vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF discontinuation changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.29 [0.82, 2.03]
8 studies · 2095 participants
Very low

Anti‐TNF disease activity–guided dose tapering vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

It is very uncertain whether anti‐TNF disease activity–guided dose tapering changes number of serious adverse events compared with anti‐TNF continuation (very low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.24 [0.42, 3.7]
2 studies · 317 participants
Very low

Anti‐TNF dose reduction vs anti‐TNF continuation

Number of serious adverse events · people with rheumatoid arthritis with low disease activity using a standard dose of anti‐TNF agents

Anti‐TNF dose reduction showed no clear difference in number of serious adverse events compared with anti‐TNF continuation (low certainty).

1 finding from 1 review

Down‐titration and discontinuation strategies of tumour necrosis factor–blocking agents for rheumatoid arthritis in… 2019 · Cochrane Headline outcomes only
RR 1.09 [0.65, 1.82]
5 studies · 1084 participants
Low

Chondroitin vs placebo

Number of serious adverse events · patients with osteoarthritis

Chondroitin probably leads to lower number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Chondroitin for osteoarthritis 2015 · Cochrane Headline outcomes only
OR 0.4 [0.19, 0.82]
6 studies · 954 participants
Moderate

COX‐2 NSAIDs vs placebo

Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)

COX‐2 NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… 2015 · Cochrane Headline outcomes only
RR 0.92 [0.14, 6.21]
669 participants
Moderate

Traditional NSAIDs vs placebo

Number of serious adverse events · patients with axSpA (AS and nr‐axSpA)

Traditional NSAIDs showed no clear difference in number of serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Non‐steroidal anti‐inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and… 2015 · Cochrane Headline outcomes only
RR 1.69 [0.36, 7.97]
671 participants
Moderate

Peginterferon alpha‐2a vs peginterferon alpha‐2b

Serious adverse events Number of events · people with chronic hepatitis C

Peginterferon alpha‐2a showed no clear difference in serious adverse events Number of events compared with peginterferon alpha‐2b (low certainty).

1 finding from 1 review

Peginterferon alpha‐2a versus peginterferon alpha‐2b for chronic hepatitis C 2014 · Cochrane Headline outcomes only
RR 1.12 [0.95, 1.3]
4 studies · 3900 participants
Low